New real-world evidence indicates that tirzepatide significantly reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The study, utilizing U.S. claims databases, compared tirzepatide against sitagliptin and found the GLP-1 agonist offered superior protection for heart health. Additionally, the data suggested a decrease in infection-related hospitalizations for patients taking the medication.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.